Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma (PEGASE2)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
pre- and post-bronchodilator VEMS value [ Time Frame: Day 0 ]
comparison of acute response to salbutamol calculated as the percentage difference between the pre- and post-bronchodilator VEMS value (BDR = 100 x [post-VEMS - pre-VEMS]/pre-VEMS) according to the genotype of the rs1504982
Secondary Outcome Measures :
Locating other regions of the PDE4 gene that may be associated with the response to salbutamol by gene mapping (using SNP tags) [ Time Frame: Day 0 ]
To identify other SNPs on PDE4 associated with the response (BDR) to salbutamol in childhood asthma.
Screening other SNPs (other genes than PDE4) associated with the response to salbutamol in childhood asthma using SNP tags [ Time Frame: Day 0 ]
To identify other genes that could be associated with the phenotype of interest (BDR) by tagging other genes.
Biospecimen Retention: Samples With DNA
Saliva from patients will be collected using Oragen®. DNA OG-575 kit, (DNA Genotek, Kanata, Canada) and stored at room temperature.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
6 Years to 18 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Children 6-18 years old asthmatic patients consulting in the Department of Pediatric Pulmonology and Allergy of Necker University Hospital.
Children 6-18 years
Asthma: confirmed asthma symptoms (wheeze, cough, dyspnea, chest tightness) and evidence for variable airflow limitation (≥ 12% increase in post bronchodilator FEV1, or ≥ 20% decrease in FEV1 post methacholine)